Abstract Library

#2827 Characterization of Epigenetic Modulation in Pancreatic Neuroendocrine Neoplasms

Introduction: Pancreatic neuroendocrine tumors (PanNETs) represent a rare and heterogeneous tumor entity. Despite advances in therapy cancer progression and resistance mechanisms are still challenging. Recent genome wide sequencing analyses in PanNETs identified a large number of mutated genes involved in epigenetic modulation.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Schmitz R

Authors: Schmitz R, Weißbach J, Kleinlein J, Schrader J, Grabowski P,

Keywords: PanNET, HDAC-Inhibition, SOCS3, lncRNA, Macrophages,

#2707 Investigating the Crosstalk between MEN1, p53 and Notch Reveals Biomarkers of Formation of Primary Pancreatic Neuroendocrine Tumors

Introduction: Pancreatic neuroendocrine tumors (PNETs) comprise a heterogeneous group of endocrine tumors. Previous studies showed that mutations of p53 are extremely rare; whereas genetic changes of MEN1 frequently occur and are correlated with poor prognosis in PNET. Still, their roles in tumorigenesis remain elusive.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Capodanno Y

Authors: Capodanno Y, Chen Y, Hiraoka N, Yokoyama A, Schrader J,

Keywords: MEN1, p53, Notch pathway, biomarkers, carcinogenesis, PNET,

#2270 Development of Pre-Clinical NEN Models – Limitations and Opportunities

Introduction: Pre-clinical research in neuroendocrine neoplasia (NEN) has long been impaired by the paucity of NET and NEC cell lines. Furthermore, established models have not been widely available or displayed unusual features (eg. p53 and ras mutations, high proliferation rate).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Schrader J

Authors: Schrader J, Benten D, Unrau L, Fahl M, Eggers C,

Keywords: cell line,

#1939 Antiproliferative Effects of Lanreotide in Neuroendocrine Tumors

Introduction: Neuroendocrine tumors of the lung (BP-NETs, typical (AC) and atypical Carcinoids (ATC)) are rare tumors with heterogeneous behavior and molecular characteristics. For the intermediate proliferating BP-NETs treatment options are limited and unsatisfactory. Somatostatin analogues have not only anti-secretory effects, but also display antiproliferative features, as shown by PROMID and CLARINET trial. Nevertheless, their value in BP-NET is undefined so far.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Grabowski P

Authors: Lelek S, Sedding D, Benecke J, Siegmund B, Schrader J,

Keywords: Bronchopulmonary neuroendocrine tumors (BP-NET), somatostatin analogues, Lanreotide, signaling,

#1869 Synergistic Effects of Combining Hsp90 and PI3K Inhibitors with Everolimus in Pancreatic Neuroendocrine Tumors

Introduction: The development of the first molecular targeted therapies for neuroendocrine tumors (NET) was a milestone in the treatment of patient. Nevertheless, these therapies eventually fail and patients become resistant to the treatment. One way of escaping this dilemma might be the combination of targeted drugs to prevent resistance development.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Schrader J

Authors: Weissmann V, Benten D, Fahl M, Eggers C, Izbicki J,

Keywords: targeted therapies, mTOR,